BRK-B vs CBAN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
CBAN presents a conflicting profile characterized by a very weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial health. While the stock trades below its Graham Number ($25.44) and maintains a reasonable P/E of 12.43, the divergence between strong revenue growth (33.9%) and stagnant earnings growth (2.4%) is concerning. Technical trends are heavily bearish (10/100), offsetting the 'Strong Buy' analyst consensus. Overall, the valuation is attractive, but the underlying financial health metrics suggest high operational risk.
Compare Another Pair
Related Comparisons
BRK-B vs CBAN: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Colony Bankcorp, Inc. (CBAN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.